Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

EYEPOINT PHARMACEUTICALS, INC.

(EYPT)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
7.910 USD   +7.04%
09/29EyePoint Pharmaceuticals Doses First Patient in Phase 2 PAVIA Clinical Trial of Eye-Disorder Treatment
MT
09/29EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy
AQ
09/29EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Extending Monday Slide

07/18/2022 | 04:05pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ETON PHARMACEUTICALS, INC. -0.94% 2.1 Delayed Quote.-51.05%
EYEPOINT PHARMACEUTICALS, INC. 7.04% 7.91 Delayed Quote.-35.38%
NABRIVA THERAPEUTICS PLC 0.97% 2.08 Delayed Quote.-86.11%
NASDAQ COMPOSITE -1.51% 10575.62 Real-time Quote.-32.40%
SHANGHAI A INDEX -0.55% 3169.6 Real-time Quote.-16.90%
SHANGHAI STOCK EXCHANGE B SHARES INDEX -0.15% 283.6251 Real-time Quote.-0.78%
ZAI LAB LIMITED -2.51% 34.2 Delayed Quote.-45.58%
All news about EYEPOINT PHARMACEUTICALS, INC.
09/29EyePoint Pharmaceuticals Doses First Patient in Phase 2 PAVIA Clinical Trial of Eye-Dis..
MT
09/29EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial ..
AQ
09/29EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial ..
CI
09/28Eyepoint Pharmaceuticals, Inc. : Other Events, Financial Statements and Exhibits (form 8-K..
AQ
09/16EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
AQ
09/14Eyepoint Pharmaceuticals : Baird 2022 Global Healthcare Conference Presentation
PU
09/13Eyepoint Pharmaceuticals : EYPT Investor Presentation September 2022
PU
09/06EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
AQ
08/31EyePoint Pharmaceuticals Plans to 'Cooperate Fully' With Subpoena Seeking Dexycu Sales ..
MT
08/30EyePoint Pharmaceuticals Plans to 'Cooperate Fully' With Subpoena Seeking Dexycu Sales ..
MT
More news
Analyst Recommendations on EYEPOINT PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 42,1 M - -
Net income 2022 -94,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,23x
Yield 2022 -
Capitalization 270 M 270 M -
Capi. / Sales 2022 6,41x
Capi. / Sales 2023 6,18x
Nbr of Employees 123
Free-Float 89,3%
Chart EYEPOINT PHARMACEUTICALS, INC.
Duration : Period :
EyePoint Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EYEPOINT PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 7,91 $
Average target price 33,67 $
Spread / Average Target 326%
EPS Revisions
Managers and Directors
Nancy Sue Lurker President, Chief Executive Officer & Director
George O. Elston CFO & Head-Corporate Development
Göran Albert Torstensson Ando Non-Executive Chairman
Dario A. Paggiarino Chief Medical Officer & Senior Vice President
Jennifer Leonard Chief People Officer & Senior Vice President-IT
Sector and Competitors
1st jan.Capi. (M$)
EYEPOINT PHARMACEUTICALS, INC.-35.38%270
JOHNSON & JOHNSON-4.51%429 503
ELI LILLY AND COMPANY19.47%307 239
ROCHE HOLDING AG-14.68%271 055
PFIZER, INC.-25.89%245 597
ABBVIE INC.-0.88%237 296